Organization
MorphoSys AG
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
MorphoSys AG
... Aggressive Lymphoma (R/R DLBCL) at ASH 2017 Conference DGAP-News: MorphoSys AG / Key word(s): Study results/Conference MorphoSys Presents Clinical Data on MOR208 ...
... Tremfya(R) (Guselkumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis in Canada DGAP-News: MorphoSys AG / Key word(s): Regulatory Approval MorphoSys Announces That Its Licensee Janssen ...
... MorphoSys has found a buyer for the Chinese rights to multiple myeloma candidate ...
... brought Synpromics on board to help its Parkinson’s gene therapy research program. MorphoSys offloaded the Chinese rights to multiple myeloma asset MOR202 to I-Mab Biopharma. ...
... DGAP-News: MorphoSys AG / Key word(s): Change in Forecast/Agreement The issuer is solely responsible ...
... Tremfya(R) (Guselkumab) in Europe for the Treatment of Moderate-to-Severe Plaque Psoriasis DGAP-News: MorphoSys AG / Key word(s): Regulatory Approval MorphoSys Announces That Its Licensee Janssen ...
... DGAP-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement Conference call and webcast ...
... What about recently approved products, such as Siliq/Kyntheum (brodalumab), and Tremfya (guselkumab; Janssen/MorphoSys)? Clinical and commercial differentiation will become critical and as the treatment landscape ...
... Compound MOR208 at Upcoming American Society of Hematology Annual Meeting 2017 DGAP-News: MorphoSys AG / Key word(s): Conference/Study results MorphoSys Announces Presentation of Clinical Data ...
... DGAP-News: MorphoSys AG / Key word(s): Change of Personnel/Miscellaneous The issuer is solely responsible ...
... Antibody MOR208 in Relapsed/Refractory DLBCL DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Receives FDA Breakthrough Therapy Designation for ...
... 3 Studies with TremfyaTM (Guselkumab) in Psoriatic Arthritis DGAP-News: MorphoSys AG / Key word(s): Study MorphoSys Announces That Its Licensee Janssen Has ...
... DGAP-News: MorphoSys AG / Key word(s): Conference Company's growth and development strategy and confirmed ...
... immuno-oncology and hematology therapeutics, today announced the end of its partnership with MorphoSys AG for the joint worldwide development and commercialization of MOR209/ES414, a targeted ...
... DGAP-News: MorphoSys AG / Key word(s): Conference present at the following conferences: MorphoSys AG ...
... Phase 2 study of XmAb®5871 in IgG4-Related Diseases (IgG4-RD), and our partner, MorphoSys, announced the initiation of a pivotal Phase 3 trial with XmAb®5574/MOR208, the ...
... survival in mesothelioma patients, causing the stocks of Bayer’s collaborators ImmunoGen and MorphoSys to slip. Investigators enrolled 248 patients with advanced malignant pleural mesothelioma (MPM) ...
... of Investigational Anetumab Ravtansine in Second-Line Mesothelioma DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Announces That Its Partner Bayer Reports ...
... Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis DGAP-News: MorphoSys AG / Key word(s): Regulatory Approval Media Release: MorphoSys Announces That Its ...
... DGAP-News: MorphoSys AG / Key word(s): Miscellaneous patients suffering from serious diseases. therapeutic antibodies ...
... Pharmaceuticals Inc, Mitotech SA, Mitsubishi Tanabe Pharma Corp, Mochida Pharmaceutical Co Ltd, MorphoSys AG, Mount Tam Biotechnologies Inc, Neuralstem Inc, Neuren Pharmaceuticals Ltd, Neurofx Inc, ...
... Combination with Lenalidomide from a Phase 2 Study in DLBCL DGAP-News: MorphoSys AG / Key word(s): Study MorphoSys Presents First Safety and Efficacy Data ...
... Development of Guselkumab DGAP-News: MorphoSys AG / Key word(s): Research Update MorphoSys Announces That Its Licensee Janssen ...
... MorphoSys AG has announced the completion of first part of a Phase I ...
... Lanthipeptide MOR107 in Healthy Volunteers DGAP-News: MorphoSys AG / Key word(s): Study results MorphoSys Announces First Results from Phase ...
Want to see the full history of news? Upgrade to RelSci Professional now!
Start My Free Trial